Description: ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
Home Page: www.abivax.com
5, rue de la Baume
Paris,
75008
France
Phone:
33 1 53 83 08 41
Officers
| Name | Title |
|---|---|
| Prof. Hartmut J. Ehrlich | Chief Exec. Officer |
| Dr. Philippe Pouletty M.D., Ph.D. | Founder & Director |
| Mr. Didier Blondel | EVP, CFO & Board Sec. |
| Ms. Raquel Lizarraga | Investor Relations Mang. |
| Ms. Regina Jehle | VP Communications |
| Anne Pascard | HR Mang. |
| Mr. Pierre Courteille M.B.A. | Chief Commercial Officer & VP of Bus. Devel. |
| Dr. Alexandra Pearce | VP of Regulatory Affairs, Quality & Pharmaco-Vigilance |
| Mr. Paul Gineste | VP Clinical Operations |
| Mr. Alain Chevallier | Sr. Advisor |
Exchange: F
Country: DE
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 21.8995 |
| Price-to-Sales TTM: | 19.9351 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 24 |